CDKN2A and neoplasm: Muscle-invasive tumors demonstrate disrupted activity of p53 and Rb and other tumor suppressors, overexpress EGFR and ErbB2, MMP2 and MMP9, and other pro-angiogenic factors, while having deleted cyclin-dependent kinase inhibitor genes CDKN2A (p16Ink4a) and CDKN2B (p15Ink4b) [4].